Interview: Caroline Schmutte, Head of the Wellcome Trust foundation office in Berlin

 

At the beginning of 2019, the British foundation Wellcome Trust opened an office in Berlin, thus expanding its activities to Germany. The first project funded by the foundation in Germany is a translation partnership with the Berlin Institute of...

More

„Just like Cambridge“ – the Boom of Biomedicine in Berlin

The pharmaceutical company Bayer wants to help turn Berlin into a biotech hub like Boston. This is possible, says head of research Stefan Oelrich in an interview with the Tagesspiegel.

More

Myelo Therapeutics Awarded NIH-NIAID Contract Valued up to $6 Million over 3 Years for Development of Myelo001 as Treatment for Acute Radiation Syndrome

Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing therapies for cancer supportive care and medical countermeasures (MCM), announced that it has been awarded a 3-year development contract valued at up to $6...

More

Unexpectedly potent protein droplets – Berlin researchers discover new pathomechanism of hereditary diseases

Repeats of individual building blocks within proteins are the cause of many hereditary diseases, but how such repeats actually cause disease is still largely unknown. Researchers in Berlin investigated how repeat elongations lead to the disease...

More

NOXXON PROVIDES UPDATE ON CLINICAL TRIAL RECRUITMENT AND CORPORATE OPERATIONS DURING COVID-19 PANDEMIC

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), provided a corporate update on its measures in response to the potential impact of...

More

Launching the COVID-19 manufacturing fund

Opening a fund to help to ensure vital parts for COVID-19 related projects are manufactured.

More

Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy

Debiopharm, a Swiss-based biopharmaceutical company announced having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development of their radioligand program,...

More

Progress towards an MVP to globally benchmark AI symptom assessments

 

“In the beginning, no one could really imagine how such complex systems like ‘AI symptom checkers’ could be benchmarked, but now this topic group is showing to be actually cracking this nut.” Developing an internationally recognized standardized...

More

Digital collaboration on rare diseases

Twenty university hospitals and other partner institutions have joined forces across Germany under the CORD-MI (Collaboration on Rare Diseases) project to improve patient care and research in the field of rare diseases. CORD-MI has been funded by the...

More

Recognise and control new variants of the deadly Ebola virus more quickly

The situation is extraordinary: there have only ever been four declarations of public health emergencies of international concern in the past and now there are two at the same time. Whilst the risks associated with the novel coronavirus are still...

More
Show more items